Golidocitinib
Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Golidocitinib is classified as a Janus kinase inhibitor.